Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Financings in Brief: CardioTech International

This article was originally published in The Gray Sheet

Executive Summary

CardioTech International: Shares of the former PolyMedica Industries unit begin trading June 12 on the American Stock Exchange. PolyMedica announced in March its plans to spin off more than 90% of outstanding shares in CardioTech to its shareholders. On June 11, PolyMedica shareholders received 0.42832 shares of CardioTech, a Woburn, Massachusetts-based developer of vascular grafts, for each PolyMedica share held. In accordance with the terms of the spin-off and due to the average trading price of CardioTech stock during its first five trading days, PolyMedica shareholders will receive an additional 0.05383 per share on June 27, 1996. The spin-off "affords both PolyMedica and CardioTech greater access to the capital markets by permitting the two companies to be evaluated independently by the financial community," PolyMedica says...

You may also be interested in...

Sandoz Denosumab Biosimilar Progressing Faster Than Anticipated

Sandoz announced more than a year ago that its GP2411 biosimilar denosumab candidate had entered the clinic. Management provided an update on its progress at the recent Virtual Meet Novartis Management Investor Event.

Dr Reddy's Adds To OTC Portfolio With Glenmark Deal

Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.

Sandoz Launches US Awareness Campaign

Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts